title: Antiproliferative activity of bortezomib alone and in combination with cisplatin or docetaxel in head and neck squamous cell carcinoma cell lines.
abstract: OBJECTIVE
  Proteasome inhibition has been shown to be effective in multiple myeloma and solid tumor models. In this in vitro study, we investigated the antitumor effect of bortezomib (Velcade((R))) in squamous cell carcinoma of the head and neck (SCCHN) cell lines and examined the interaction of the drug with docetaxel (TAX) and cisplatin (CDDP).
  
  
  METHODS
  Dose escalation studies were performed with eight squamous cell carcinoma cell lines using bortezomib alone or in combination with TAX or CDDP. Growth inhibitory and proapoptotic effects were measured quantitatively using cytohistology and western blot analysis.
  
  
  RESULTS
  Bortezomib alone showed a significant antiproliferative activity in all SCCHN cell lines (P = 0.012), and the activity was further enhanced by the addition of TAX or CDDP (P </= 0.036). When the combination of bortezomib and CDDP was used, the dose of the latter could be reduced to yield the same antiproliferative effect as the cytotoxic drug alone (P < 0.012).
  
  
  CONCLUSIONS
  Our results indicate that bortezomib increases the cytotoxic activity of TAX and CDDP in SCCHN cell lines. In vivo and in the clinical setting, the addition of bortezomib may allow to reduce the doses of TAX or CDDP to decrease the systemic toxicity of these drugs.
authors: ENT Department, Medical School, Goethe University, Frankfurt am Main, Germany.
authors: Jens
authors: J
authors: Wagenblast
authors: Markus
authors: M
authors: Hambek
authors: Mehran
authors: M
authors: Baghi
authors: Wolfgang
authors: W
authors: Gstöttner
authors: Klaus
authors: K
authors: Strebhardt
authors: Hanns
authors: H
authors: Ackermann
authors: Rainald
authors: R
authors: Knecht
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology* / Q000627:therapeutic use; D001897:Boronic Acids / Q000494:pharmacology* / Q000627:therapeutic use; D000069286:Bortezomib; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002945:Cisplatin / Q000494:pharmacology* / Q000627:therapeutic use; D000077143:Docetaxel; D004305:Dose-Response Relationship, Drug; D004354:Drug Screening Assays, Antitumor; D006258:Head and Neck Neoplasms / Q000188:drug therapy*; D006801:Humans; D011719:Pyrazines / Q000494:pharmacology* / Q000627:therapeutic use; D043823:Taxoids / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D001897:Boronic Acids; D011719:Pyrazines; D043823:Taxoids; D000077143:Docetaxel; D000069286:Bortezomib; D002945:Cisplatin
references: Mol Cancer Ther. 2004 Jan;3(1):59-70
references: 14749476
references: Epidemiol Prev. 2004 Mar-Apr;28(2 Suppl):28-33
references: 15281603
references: Mol Cell Biol. 2004 Nov;24(22):9695-704
references: 15509775
references: Asian Pac J Cancer Prev. 2006 Apr-Jun;7(2):195-200
references: 16839210
references: Gan To Kagaku Ryoho. 2005 Dec;32(13):2035-9
references: 16352925
references: Mol Cancer Ther. 2002 Aug;1(10):841-9
references: 12492117
references: Curr Pharm Biotechnol. 2006 Dec;7(6):441-8
references: 17168660
references: Clin Cancer Res. 2003 Oct 1;9(12):4537-45
references: 14555528
references: Cancer Sci. 2004 Feb;95(2):176-80
references: 14965369
references: J Clin Oncol. 2006 Nov 1;24(31):5025-33
references: 17075122
references: Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):2727-30
references: 9501156
references: J Clin Oncol. 1992 Feb;10(2):257-63
references: 1732427
references: Anticancer Agents Med Chem. 2007 May;7(3):359-65
references: 17504161
references: Nat Rev Cancer. 2004 May;4(5):349-60
references: 15122206
references: Clin Lung Cancer. 2004 Dec;6 Suppl 2:S89-96
references: 15638966
references: J Biol Chem. 2006 Oct 20;281(42):31440-7
references: 16928686
references: Clin Cancer Res. 2003 Mar;9(3):1145-54
references: 12631620
references: Anticancer Res. 1998 Nov-Dec;18(6B):4779-86
references: 9891557
references: Cancer Treat Rev. 2003 May;29 Suppl 1:41-8
references: 12738242
references: Cancer Chemother Pharmacol. 2004 Oct;54(4):343-53
references: 15197486
references: Cancer Treat Rev. 2003 May;29 Suppl 1:21-31
references: 12738240
references: J Clin Oncol. 1992 Aug;10(8):1245-51
references: 1634913
references: Eur J Cancer. 2004 Oct;40(15):2217-29
references: 15454246
references: Ann Oncol. 1994 Jul;5(6):521-6
references: 7522527
references: J Clin Oncol. 1998 Mar;16(3):1054-9
references: 9508190
references: J Clin Oncol. 2001 Feb 15;19(4):1088-95
references: 11181673
references: Clin Cancer Res. 2006 Feb 15;12(4):1270-5
references: 16489083